U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H28FO8P.2Na
Molecular Weight 516.4046
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXAMETHASONE SODIUM PHOSPHATE

SMILES

[Na+].[Na+].[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COP([O-])([O-])=O)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=PLCQGRYPOISRTQ-FCJDYXGNSA-L
InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H28FO8P
Molecular Weight 470.4251
Charge -2
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/67018038

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune response. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

1962
Primary
MAXIDEX

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

1962
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

1962
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

1962
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

1962
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

1962
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

1962
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

1962
Primary
Neofordex

Approved Use

Neofordex is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.

Launch Date

2016
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.87 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
51.2 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.93 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
DEXAMETHASONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
96 mg multiple, oral (total)
Dose: 96 mg
Route: oral
Route: multiple
Dose: 96 mg
Sources:
unhealthy, 63 years (range: 30–78 years)
n = 21
Health Status: unhealthy
Age Group: 63 years (range: 30–78 years)
Sex: M+F
Population Size: 21
Sources:
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
n = 77
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Population Size: 77
Sources:
Other AEs: Corneal erosion...
Other AEs:
Corneal erosion (10%)
Sources:
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
n = 6
Health Status: unhealthy
Condition: Migraine
Age Group: children
Population Size: 6
Sources:
Other AEs: Constipation...
Other AEs:
Constipation (below serious, 1 patient)
Sources:
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Other AEs: Drowsiness, Dizziness...
Other AEs:
Drowsiness (below serious, 19 patients)
Dizziness (below serious, 3 patients)
Adverse drug reaction NOS (below serious, 10 patients)
Sources:
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Other AEs: Wound dehiscence...
Other AEs:
Wound dehiscence (below serious, 1 patient)
Sources:
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Other AEs: Dizziness...
Other AEs:
Dizziness (below serious, 1 patient)
Sources:
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Other AEs: Constipation, Dyspepsia...
Other AEs:
Constipation (below serious, 47 patients)
Dyspepsia (below serious, 12 patients)
Vomiting (below serious, 9 patients)
Fatigue (below serious, 58 patients)
Cholesterol high (below serious, 8 patients)
Anorexia (below serious, 15 patients)
Anxiety (below serious, 11 patient)
Insomnia (below serious, 26 patients)
Cough (below serious, 9 patients)
Dyspnea (below serious, 20 patients)
Sources:
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Other AEs: Incision site bleeding, Body temperature decrease...
Other AEs:
Incision site bleeding (below serious, 1 patient)
Body temperature decrease (below serious, 2 patients)
Shivering (below serious, 1 patient)
Tachycardia (below serious, 1 patient)
Transfusion (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Corneal erosion 10%
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
n = 77
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Population Size: 77
Sources:
Constipation below serious, 1 patient
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
n = 6
Health Status: unhealthy
Condition: Migraine
Age Group: children
Population Size: 6
Sources:
Adverse drug reaction NOS below serious, 10 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Drowsiness below serious, 19 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Dizziness below serious, 3 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Wound dehiscence below serious, 1 patient
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Dizziness below serious, 1 patient
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Anxiety below serious, 11 patient
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Dyspepsia below serious, 12 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Anorexia below serious, 15 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Dyspnea below serious, 20 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Insomnia below serious, 26 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Constipation below serious, 47 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Fatigue below serious, 58 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Cholesterol high below serious, 8 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Cough below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Vomiting below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Incision site bleeding below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Shivering below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Tachycardia below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Transfusion below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Body temperature decrease below serious, 2 patients
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: These data demonstrate that dexamethasone at doses used clinically increased CYP3A4 activity with extensive intersubject variability and that the extent of CYP3A4 induction was, in part, predicted by the baseline activity of CYP3A4 in both healthy volunteers and human hepatocyte cultures.
Page: -
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Effects of dexamethasone on tumor-induced brain edema and its distribution in the brain of monkeys.
1979 Mar
The role of pulmonary inflammation in the development of pulmonary hypertension in newborn with meconium aspiration syndrome (MAS).
1999
ECC-1 human endometrial cells as a model system to study dioxin disruption of steroid hormone function.
1999 Apr
Functional assay of NF-kappaB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline.
1999 Apr
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
1999 Aug 12
Inhibition of transforming growth factor beta1-induced hepatoma cell apoptosis by liver tumor promoters: characterization of primary signaling events and effects on CPP32-like caspase activity.
1999 Feb
Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
1999 Feb
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.
1999 Jul
The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation.
1999 Mar
Pharmacological validation of a feline model of steroid-induced ocular hypertension.
1999 Mar
Effect of dexamethasone on cyclophosphamide-induced cystitis in rats: lack of relation with bradykinin B1 receptor-mediated motor responses.
1999 Mar 12
Effect of arsenite on induction of CYP1A, CYP2B, and CYP3A in primary cultures of rat hepatocytes.
1999 May 15
Dexamethasone therapy increases infection in very low birth weight infants.
1999 Nov
Antenatal dexamethasone suppresses tumor necrosis factor-alpha expression in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
1999 Nov
Early (4-7 days of age) dexamethasone therapy for prevention of chronic lung disease in preterm infants.
1999 Nov
Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats.
1999 Sep
Antenatal dexamethasone improves atrial natriuretic peptide receptors in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
2000
Immune abnormalities in aneurysmal subarachnoid haemorrhage patients: relation to delayed cerebral vasospasm.
2000 Apr
Dexamethasone suppresses tumor necrosis factor-alpha-induced apoptosis in osteoblasts: possible role for ceramide.
2000 Aug
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
2000 Aug
Dexamethasone-suppressible hypertension.
2000 Aug 26
Acrylamide-regulated neurofilament expression in rat pheochromocytoma cells.
2000 Jan 10
Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up.
2000 Jun
Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding.
2000 Jun 23
Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line.
2000 Mar
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
2000 Mar 1
Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands.
2000 May 19
Regulation of leptin release by troglitazone in human adipose tissue.
2000 Nov
Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats.
2000 Nov
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.
2000 Nov 10
Antenatal dexamethasone enhances surfactant protein synthesis in the hypoplastic lung of nitrofen-induced diaphragmatic hernia in rats.
2000 Oct
Endotoxin augments cerebral hyperemic response to halothane by inducing nitric oxide synthase and cyclooxygenase.
2000 Oct
Endocrinologic and psychological effects of short-term dexamethasone in anorexia nervosa.
2000 Sep
A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide.
2001 Feb
Molecular and pharmacological evidence for modulation of kinin B(1) receptor expression by endogenous glucocorticoids hormones in rats.
2001 Jan
Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen.
2001 Jan
Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.
2001 Jan 11
Topical 0.1% indomethacin solution versus topical 0.1% dexamethasone solution in the prevention of inflammation after cataract surgery. The Study Group.
2001 Jan-Feb
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
2012 Nov
Patents

Sample Use Guides

One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly. In mild disease, drops may be used up to four to six times daily.
Route of Administration: Other
Caco-2 cells were treated with 1 μM dexamethasone and SGK1 mRNA levels were determined by Northern blot analysis. Figure 1A shows that dexamethasone rapidly induced SGK1 mRNA expression as early as 30 min and maintained the elevated expression for at least 24 h.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:35:21 GMT 2023
Edited
by admin
on Fri Dec 15 15:35:21 GMT 2023
Record UNII
AI9376Y64P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXAMETHASONE SODIUM PHOSPHATE
EP   GREEN BOOK   JAN   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE [VANDF]
Common Name English
DEXABENE
Brand Name English
MEPHAMESONE
Brand Name English
DEXADRESON
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE [WHO-IP]
Common Name English
MEGACORT
Common Name English
ORADEXON
Brand Name English
TLC-399
Code English
DEXACORT
Brand Name English
DEXAMETHASONE DISODIUM PHOSPHATE
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE [USP IMPURITY]
Common Name English
PRODEX
Brand Name English
9-Fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 21-(dihydrogen phosphate) disodium salt
Common Name English
SOLUDECADRON
Brand Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,17-DIHYDROXY-16-METHYL-21-(PHOSPHONOOXY)-, DISODIUM SALT, (11.BETA.,16.ALPHA.)-
Common Name English
TLC399
Code English
AK-DEX
Brand Name English
Dexamethasone sodium phosphate [WHO-DD]
Common Name English
DALALONE
Brand Name English
DEXAMETHASONE SODIUM PHOSPHATE [JAN]
Common Name English
NSC-756722
Code English
DEXAMETHASONE SODIUM PHOSPHATE [GREEN BOOK]
Common Name English
DEXAMETHASONE PHOSPHATE (AS SODIUM)
Common Name English
TOTOCORTIN
Brand Name English
DEXACEN-4
Brand Name English
DEXAMETHASONE 21-PHOSPHATE DISODIUM SALT [MI]
Common Name English
ORGADRONE
Brand Name English
SOLDESAM
Brand Name English
NEODECADRON COMPONENT DEXAMETHASONE SODIUM PHOSPHATE
Common Name English
DEXAIR
Brand Name English
DEXAMETHASONE SODIUM PHOSPHATE [USP MONOGRAPH]
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE COMPONENT OF NEODECADRON
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE [ORANGE BOOK]
Common Name English
DEXAMETHASONE 21-PHOSPHATE DISODIUM SALT
MI  
Common Name English
TURBINAIRE
Common Name English
SOLUPEN N
Brand Name English
DEXAMETHASONI NATRII PHOSPHAS [WHO-IP LATIN]
Common Name English
DEXAMETHASONE SODIUM PHOSPHATE [USP-RS]
Common Name English
DECADRON PHOSPHATE
Brand Name English
DEXAMETHASONE SODIUM PHOSPHATE [MART.]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 373212
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
NCI_THESAURUS C521
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
EU-Orphan Drug EU/3/13/1158
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
Code System Code Type Description
PUBCHEM
16961
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
CHEBI
41879
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
RXCUI
48933
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY RxNorm
CHEBI
4462
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
RS_ITEM_NUM
1177032
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
NSC
756722
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
ECHA (EC/EINECS)
219-243-0
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
SMS_ID
100000090542
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201302
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
NCI_THESAURUS
C1362
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
FDA UNII
AI9376Y64P
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
DRUG BANK
DBSALT000843
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
CAS
2392-39-4
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
MERCK INDEX
m4215
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY Merck Index
EVMPD
SUB01615MIG
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
DAILYMED
AI9376Y64P
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
EVMPD
SUB122698
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
ALTERNATIVE
WHO INTERNATIONAL PHARMACOPEIA
DEXAMETHASONE SODIUM PHOSPHATE
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder.Solubility: Freely soluble in water; slightly soluble in ethanol (~750 g/L) TS; practically insoluble in dichloromethane R.Category: Adrenal hormone.Storage: Dexamethasone sodium phosphate should be kept in a tightly closed container, protected from light.Additional information: Dexamethasone sodium phosphate is very hygroscopic. Even in the absence of light it is graduallydegraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Dexamethasone sodiumphosphate may exhibit polymorphism.
EPA CompTox
DTXSID3047429
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
MESH
C004180
Created by admin on Fri Dec 15 15:35:22 GMT 2023 , Edited by admin on Fri Dec 15 15:35:22 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
correction factor: for the calculation of content, multiply the peak area of impurity A by 0.75
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY